Silymarin: an insight to its formulation and analytical prospects

• Autorzy: Ahmad U. , Faiyazuddin M. , Hussain M.T. , Ahmad S. , Alshammari T.M. , Shakeel F.
• Języki publikacji: EN

Abstrakty

EN

Silymarin, a potential phytochemical compound obtained from the seeds of Silybum marianum plant has been used as a hepatoprotective agent for more than a decade. So far, eight active components of silymarin flavonolignans have been identified, among which silibinin has been proven the most active. However, it had poor oral bioavailability due to extensive phase II metabolism, low permeability across intestinal epithelial cells, low aqueous solubility, and rapid excretion in bile and urine. Therefore it becomes necessary to understand all its formulation and analytical aspects from past to present, including all of its possible future prospects. In modern research scenario, nanotization strategies of drugs has served as a potential approach to enhance solubility, bioavailability and to develop a robust formulation. Several approaches have been utilized previously to enhance the solubility and bioavailability of silymarin to provide it a robust strength against physical, chemical, and environmental degradation. Nanoscale formulations such as nanoemulsion, nanosuspension, liposomes, and solid–lipid nanoparticles can be used to enhance solubility and to target them to desired cells with minimum harm to normal cells. However, many other approaches exist such as dendrimers, ceramic nanoparticles, and carbon nanotubes, which serve as a great vehicle in drug delivery to transport medicament at target sites. Therefore, the purpose of this review was to develop a better understanding of the problems associated with silymarin and approaches to overcome the difficulties to develop a better and stable formulation for food and pharmaceutical applications.

• Wydawca: -
• Czasopismo: Acta Physiologiae Plantarum
• Rocznik: 2015
• Tom: 37
• Numer: 11
• Opis fizyczny: Article: 253 [17 p.], fig.,ref.

Twórcy

autor

Ahmad U.

• Department of Pharmaceutics, Faculty of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India

autor

Faiyazuddin M.

• Department of Pharmaceutics, College of Pharmacy, University of Hail, P.O. Box 2440, Hail, Saudi Arabia

autor

Hussain M.T.

• Department of Pharmacology and Toxicology, College of Pharmacy, University of Hail, P.O. Box 2440, Hail, Saudi Arabia

autor

Ahmad S.

• Department of Clinical Pharmacy, College of Pharmacy, Jazan University, Jazan, Saudi Arabia

autor

Alshammari T.M.

• Department of Clinical Pharmacy, College of Pharmacy, University of Hail, P. O. Box 2440, Hail, Saudi Arabia

autor

Shakeel F.

• Center of Excellence in Biotechnology Research (CEBR), King Saud University, P.O. Box 2460, Riyadh, 11451, Saudi Arabia

Bibliografia

• Abrol S, Trehan A, Katare OP (2004) Formulation, characterization, and in vitro evaluation of silymarin-loaded lipid microspheres. Drug Deliv 11:185–191
• Abrol S, Trehan A, Katare OP (2005) Comparative study of different silymarin formulations: formulation, characterisation and in vitro/in vivo evaluation. Curr Drug Deliv 2:45–51
• Ajazuddin, Saraf S (2010) Applications of novel drug delivery system for herbal formulations. Fitoter 81:680–689
• Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5:505–515
• Angelos S, Johansson E, Stoddart JF, Zink JI (2007) Mesostructured silica supports for functional materials and molecular machines. Adv Funct Mater 17:2261–2271
• Arcari M, Brambilla A, Brandt A, Caponi R, Corsi G, Di-Rella M, Solinas F, Wachter WP (1992) A new inclusion complex of silibinin and beta-cyclodextrins: in vitro dissolution kinetics and in vivo absorption in comparison with traditional formulations. Boll Chim Farm 131:205–209
• Aungst BJ, Nguyen N, Rogers NJ, Rowe S, Hussain M, Shum L, White S (1994) Improved oral bioavailability of an HIV protease inhibitor using Gelucire 44/14 and Labrasol vehicles. Bull Tech Gatt 87:49–54
• Bai TC, Yan GB, Zhang HL, Hu J (2005) Solubility of silybin in aqueous dextran solutions. J Chem Eng Data 50:1596–1601
• Bai TC, Yan GB, Hu J, Zhang HL, Huang CG (2006) Solubility of silybin in aqueous poly(ethylene glycol) solution. Int J Pharm 308:100–106
• Bai TC, Zhu JJ, Hu J, Zhang HL, Huang CG (2007) Solubility of silybin in aqueous hydrochloric acid solution. Fluid Phase Equilib 254:204–210
• Bianco A, Kostarelos K, Prato M (2005) Applications of carbon nanotubes in drug delivery. Curr Opin Chem Biol 9:674–679
• Boas U, Heegaard PM (2004) Dendrimers in drug research. Chem Soc Rev 33:43–63
• Broadwith P (2010) Are nanotubes the future for radiotherapy? Royal Society of Chemistry. http://www.rsc.org/chemistryworld/News/2010/September/01091001.asp (Accessed 18 Sept 2014)
• Bruce JA (2006) Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J Pharm Sci 82:979–987
• Burcham DL, Maurin MB, Hausner EA, Huang SM (1997) Improved oral bioavailability of the hypocholesterolemic DMP 565 in dogs following oral dosing in oil and glycol solutions. Biopharm Drug Disp 18:737–742
• Cai XL, Li DN, Qio JQ, Lian HZ, Wang SK (2009) Determination of silymarin flavonoids by HPLC and LC–MS and investigation of extraction rate of silymarin in Silybum marianum fruits by boiling water. Asian J Chem 21:63–74
• Cao Z, Ma Y, Yue X, Li S, Dai Z, Kikuchi J (2010) Stabilized liposomal nanohybrid cerasomes for drug delivery applications. Chem Commun 46:5265–5267
• Cloninger MJ (2002) Biological applications of dendrimers. Curr Opin Chem Biol 6:742–748
• Constantinides PP (1995) Lipid microemulsions for improving drug dissolution and oral absorption and biopharmaceutical aspects. Pharm Res 12:1561–1572
• Danhier OF, Preat V (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148:135–146
• Descalzo AB, Martinez-Manez R, Sancenon F, Hoffmann K, Rurack K (2006) The supramolecular chemistry of organic inorganic hybrid materials. Angew Chem Int Ed Engl 45:5924–5948
• Dresselhaus MS, Dresselhaus G, Avouris P (2001) Carbon nanotubes synthesis, structure, properties, and applications. In: Topics in applied physics, vol XV. Heidelberg, p 448
• Dube D, Khatri K, Goyal AK, Mishra N, Vyas SP (2010) Preparation and evaluation of galactosylated vesicular carrier for hepatic targeting of silibinin. Drug Dev Ind Pharm 36:547–555
• Eccleston GM (1992) Microemulsion. In: Swarbick I, Boylan JC (eds) Encyclopedia of pharmaceutical technology, vol 9. Marcel Dekker, New York, pp 375–421
• El-Samaligy MS, Afifi NN, Mahmoud EA (2006) Evaluation of hybrid liposomes-encapsulated silymarin regarding physical stability and in vivo performance. Int J Pharm 319:121–129
• Fang JY (2006) Nano or submicron-sized liposomes as carriers for drug delivery. Chang Gung Med J 29:358–362
• Feazell RP, Nakayama-Ratchford N, Dai H, Lippard SJ (2007) Soluble single-walled carbon nanotubes as longboat delivery systems for platinum (IV) anticancer drug design. J Am Chem Soc 129:8438–8439
• Filburn CR, Kettenacker R, Griffin DW (2007) Bioavailability of a silybin-phosphatidylcholine complex in dogs. J Vet Pharmacol Ther 30:132–138
• Flora K, Hahn M, Rosen H, Benner K (1998) Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 93:139–143
• Foster S (1996) Milk thistle Silybum marianum. Botanical Series No. 305, 2nd edn. American Botanical Council, Austin
• Garg R, Gupta GD (2009) Preparation and evaluation of gastroretentive floating tablets of silymarin. Chem Pharm Bull 57:545–549
• Gazák R, Svobodová A, Psotová J, Sedmera P, Prikrylová V, Walterová D, Kren V (2004) Oxidised derivatives of silybin and their antiradical and antioxidant activity. Bioorg Med Chem 12:5677–5687
• Ghosh A, Biswas S, Ghosh T (2011) Preparation and evaluation of silymarin b-cyclodextrin molecular inclusion complexes. J Young Pharm 3:205–210
• Gill B, Singh J, Sharma V, Kumar SLH (2012) Emulsomes: an emerging vesicular drug delivery system. Asian J Pharm 6:87–94
• Hadad GM, Emara S, Abdel-Salam RA (2009) Validated optimized method for simultaneous analysis of active silymarin components and dimethyl-4, 40-dimethoxy-5, 6, 50, 60-dimethylene dioxybiphenyl-2, 20-dicarboxylate in a pharmaceutical preparation by use of a monolithic silica C18 column. Chromatographia 70:217–221
• Hans ML, Lowman AM (2002) Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 6:319–327
• Hashizume M, Kawanami SI, Iwamoto S, Isomoto T, Kikuchi JI (2003) Stable vesicular nanoparticle ‘Cerasome’ as an organic–inorganic hybrid formed with organoalkoxysilane lipids having a hydrogen-bonding unit. Thin Solid Films 438:20–26
• He J, Feng JF, Zhang LL, Lu WG, Hou SX (2005) Freeze-drying of silymarin-loaded solid lipid nanoparticles (SM-SLN). Zhongguo Zhong Yao Za Zhi 30:110–112
• He J, Hou S, Lu W, Zhu L, Feng J (2007) Preparation, pharmacokinetics and body distribution of silymarin-loaded solid lipid nanoparticles after oral administration. J Biomed Nanotechnol 3:195–202
• Hillaireau H, Couvreur P (2009) Nanocarriers’ entry into the cell: relevance to drug delivery. Cell Mol Life Sci 66:2873–2896
• Hui Z, Huihua L (2011) Preparation of silymarin nanosuspension by microemulsion dilution. Chinese Scientific Papers Online. http://www.paper.edu.cn/en_releasepaper/content/4442628
• Jadhav KR, Shaikh IM, Ambade KW, Kadam VJ (2006) Applications of microemulsion based drug delivery system. Curr Drug Deliv1:267–273
• Jaganath S, Palanichamy S, Buhary SSM, Rajesh M, Prabhu C, Thirupathi AT (2011) Preparation and evaluation of silymarin controlled release tablets prepared using natural gums. Int J Pharm Sci Drug Res 4:1369–1372
• Jain KK (2012) The Handbook of Nanomedicine. Humana Press, Totowa Jancová P, Anzenbacherová E, Papousková B, Lemr K, Luzná P, Veinlichová A, Anzenbacher P, Simánek V (2007) Silybin is metabolized by cytochrome P450 2C8 in vitro. Drug Metab Dispos 35:2035–2039
• Javed S, Kohli K, Ali M (2011) Reassessing bioavailability of silymarin. Altern Med Rev 16:239–249
• Jia LJ, Zhang DR, Li ZY, Feng FF, Wang YC, Dai WT, Duan CX, Zhang Q (2010) Preparation and characterization of silybinloaded nanostructured lipid carriers. Drug Deliv 17:11–18
• Kam NWS, Dai H (2005) Carbon nanotubes as intracellular protein transporters: generality and biological functionality. J Am Chem Soc 127:6021–6026
• Kam NW, O’Connell M, Wisdom JA, Dai H (2005) Carbon nanotubes as multifunctional biological transporters and nearinfrared agents for selective cancer cell destruction. Proc Natl Acad Sci 102:11600–11605
• Kam NWS, Liu Z, Dai H (2006) Carbon nanotubes as intracellular transporters for proteins and DNA: an investigation of the uptake mechanism and pathway. Angew Chem Int Ed Engl 45:577–5781
• Kararli TT, Needham TE, Griffin M, Schoenhard G, Ferro LJ, Alcorn L (1992) Oral delivery of a renin inhibitor compound using emulsion formulations. Pharm Res 9:888–893
• Karkanis A, Bilalis D, Efthimiadou A (2011) Cultivation of milk thistle (Silybum marianum L. Gaertn.), a medicinal weed. Ind Crops Prod 34:825–830
• Katagiri K, Hamasaki R, Ariga K, Kikuchi J (2003) Preparation and surface modification of novel vesicular nano-particle ‘cerasome’ with liposomal bilayer and silicate surface. J Sol-Gel Sci Technol 26:393–396
• Katagiri K, Hashizume M, Ariga K, Terashima T, Kikuchi J (2007) Preparation and characterization of a novel organic–inorganic nanohybrid ‘‘cerasome’’ formed with a liposomal membrane and silicate surface. Chemistry 13:5272–5281
• Khuda-Bukhsh AR, Bhattacharyya SS, Paul S, Boujedaini N (2010) Polymeric nanoparticle encapsulation of a naturally occurring plant scopoletin and its effects on human melanoma cell A375. Zhong Xi Yi Jie He Xue Bao 8:853–862
• Kim S, Choi MG, Lee HS, Lee SK, Kim SH, Kim WW, Hur SM, Kim JH, Choe JH, Nam SJ, Yang JH, Kim S, Lee JE, Kim JS (2009) Silibinin suppresses TNF-alpha-induced MMP-9 expression in gastric cancer cells through inhibition of the MAPK pathway. Molecules 14:4300–4311
• Kommuru TR, Gurley B, Khan MA, Reddy IK (2001) Selfemulsifying drug delivery systems (SEDDS) of enzyme Q10: formulation development and bioavailability assessment. Int J Pharm 212:233–246
• Korany MA, Haggag RS, Ragab MA, Elmallah OA (2013) A validated stability-indicating HPLC method for simultaneous determination of silymarin and curcumin in various dosage forms. Arab J Chem. doi:10.1016/j.arabjc.2013.06.021
• Kosina P, Kren V, Gebhardt R, Grambal F, Ulrichová J, Walterová D (2002) Antioxidant properties of silybin glycosides. Phytother Res 1:33–39
• Kosina P, Maurel P, Ulrichová J, Dvorák Z (2005) Effect of silybin and its glycosides on the expression of cytochromes P450 1A2 and 3A4 in primary cultures of human hepatocytes. J Biochem Mol Toxicol 19:149–153
• Kuki Á , Nagy L, Deák G, Nagy M, Zsuga M, Kéki S (2012) Identification of silymarin constituents: an improved HPLC–MS method. Chromatographia 75:175–180
• Kumar D, Sharma D, Singh G, Singh M, Rathore MS (2012) Lipoidal soft hybrid biocarriers of supramolecular construction for drug delivery. ISRN Pharm 2012:E474830
• Kumar N, Rai A, Reddy ND, Raj PV, Jain P, Deshpande P, Mathew G, Kutty NG, Udupa N, Rao CM (2014) Silymarin liposomes improves oral bioavailability of silybin besides targeting hepatocytes, and immune cells. Pharmacol Rep 66:788–798
• Kumari A, Yadav SK, Yadav SC (2010) Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 75:1–18
• Lawrence MJ (1996) Microemulsion as drug delivery vehicles. Curr Opin Colloids Interface Sci 1:826–832
• Lawrence MJ, Rees GD (2000) Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 45:89–121
• Leuner C, Dressman J (2000) Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 50:47–60
• Li FQ, Hu JH (2004) Improvement of the dissolution rate of silymarin by means of solid dispersions. Chem Pharm Bull 52:972–973
• Li FQ, Hu JH, Wang H, Zhu QG, Sun HJ, Cai Z (2002) Relativities between lattice changes and the function of dissolution improvement of poorly soluble drug silymarin based upon PEG 6,000 solid dispersion system. Yao Xue Xue Bao 37:294–298
• Ligeret H, Brault A, Vallerand D, Haddad Y, Haddad PS (2008) Antioxidant and mitochondrial protective effects of silibinin in cold preservation-warm reperfusion liver injury. J Ethnopharmacol 115:507–514
• Liu Y, Wu DC, Zhang WD, Jiang X, He CB, Chung TS, Goh SH, Leong KW (2005) Polyethylenimine-grafted multiwalled carbon nanotubes for secure noncovalent immobilization and efficient delivery of DNA. Angew Chem Int Ed Engl 44:4782–4785
• Liu Z, Sun X, Nakayama-Ratchford N, Dai H (2007a) Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery. ACS Nano 1:50–56
• Liu Z, Cai W, He L, Nakayama N, Chen K, Sun X, Chen X, Dai H (2007b) In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol 2:47–52
• Liu Z, Winters M, Holodniy M, Dai H (2007c) SiRNA delivery into human T cells and primary cells with carbon nanotube transporters. Angew Chem Int Ed Engl 46:2023–2027
• Liu Z, Davis C, Cai W, He L, Chen X, Dai H (2008) Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc Natl Acad Sci 105:1410–1415
• Lu C, Lu Y, Chen J, Zhang W, Wu W (2007) Synchronized and sustained release of multiple components in silymarin from erodible glycerylmonostearate matrix system. Eur J Pharm Biopharm 66:210–219
• Luper S (1998) A review of plants used in the treatment of liver disease: part 1. Altern Med Rev 3:410–421
• Madaus RHH, Halbach G, Trost W (1976) Salt of the silymarin group with aminopolyhydroxy alcohols. US Patent 3,994,925
• Maheshwari H, Agarwal R, Patil C, Katare OP (2003) Preparation and pharmacological evaluation of silibinin liposomes. Arzneimittelforschung 53:420–427
• Mainardes RM, Silva LP (2004) Drug delivery systems: past, present, and future. Curr Drug Targets 5:449–455
• Mainardes RM, Gremião MPD, Evangelista RC (2006) Thermoanalytical study of praziquatel-loaded PLGA nanoparticles. Br J Pharm Sci 42:523–530
• McDevitt MR, Chattopadhyay D, Kappel BJ, Jaggi JS, Schiffman SR, Antczak C, Njardarson JT, Brentjens R, Scheinberg DA (2007) Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nucl Med 48:1180–1189
• McNeil SE (2009) Nanoparticle therapeutics: a personal perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1:264–271
• Meghreji MA, Patel CN, Dave JB, Badmanaban R, Patel JA (2010) Validated method for silymarin by spectrophotometry in bulk drug and pharmaceutical formulations. J Chem Pharm Res 2:396–400
• Morazzoni P, Bombardelli E (1995) Silybum marianum (Carduusmarianus). Fitoter 66:3–42
• Morazzoni P, Montalbetti A, Malandrino S, Pifferi G (1993) Comparative pharmacokinetics of silipide and silymarin in rats. Eur J Drug Metab Pharmacokinet 18:289–297
• Morgan MT, Nakanishi Y, Kroll DJ, Griset AP, Carnahan MA, Wathier M, Oberlies NH, Manikumar G, Wani MC, Grinstaff MW (2006) Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro. Cancer Res 66:11913–11921
• Müller RH, Mäder K, Gohla S (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm 50:161–177
• Mulrow C, Lawrence V, Jacobs B, Dennehy C, Sapp J, Ramirez G, Aguilar C, Montgomery K, Morbidoni L, Arterburn JM, Chiquette E, Harris M, Mullins D, Vickers A, Flora K (2000)
• Milk thistle: effects on liver disease and cirrhosis and clinical adverse effects: summary. Evid Rep Technol Assess 21:1–3
• Myers RA, Stella VJ (1992) Systemic bioavailability of penclomedine (NSC-338720) from oil-in-water emulsions administered intraduodenally to rats. Int J Pharm 78:217–226
• Nakhat PD, Naidu RA, Babla IB, Khan S, Yeole PG (2007) Design and evaluation of silymarin-HPbeta- CD solid dispersion tablets. Ind J Pharm Sci 69:287–289
• NNI (2005) National nanotechnology initiative: research and development leading to a revolution in technology and industry, office of sciences and technology policy, Washington, DC, USA. http://www.nano.gov/nanotech-101/what
• Palin KJ, Phillips AJ, Ning A (1986) The oral absorption of cefoxitin from oil and emulsion vehicles in rats. Int J Pharm 33:99–104
• Paliwal R, Paliwal SR, Mishra N, Mehta A, Vyas SP (2009) Engineered chylomicron mimicking carrier emulsome for lymph targeted oral delivery of methotrexate. Int J Pharm 380:181–188
• Panapisal V, Charoensri S, Tantituvanont A (2012) Formulation of microemulsion systems for dermal delivery of silymarin. AAPS PharmSciTech 13:389–399
• Pantarotto D, Briand JP, Prato M, Bianco A (2004) Translocation of bioactive peptides across cell membranes by carbon nanotubes. Chem Commun 7:16–17
• Pardeike J, Hommoss A, Müller RH (2009) Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 366:170–184
• Parveen R, Ahmad S, Baboota S, Ali J, Ahuja A (2010) Stabilityindicating HPTLC method for quantitative estimation of silybin in bulk drug and pharmaceutical dosage form. Biomed Chromatogr 24:639–647
• Parveen R, Baboota S, Ali J, Ahuja A, Vasudev SS, Ahmad S (2011a) Oil based nanocarrier for improved oral delivery of silymarin: in vitro and in vivo studies. Int J Pharm 413:245–253
• Parveen R, Baboota S, Ali J, Ahuja A, Vasudev SS, Ahmad S (2011b) Effects of silymarinnanoemulsion against carbon tetrachlorideinduced hepatic damage. Arch Pharm Res 34:767–774
• Ph. Eur. (2008) European Pharmacopoeia Commission. European Pharmacopoeia, 6th edn, vol 2
• Pifferi G, Pace R, Conti M (1994) Synthesis and antihepatotoxic activity of silybin 11-O-phosphate. Farmaco 49:75–76
• Quaglia MG, Bossú E, Donati E, Mazzanti G, Brandt A (1999) Determination of silymarine in the extract from the dried Silybum marianum fruits by high performance liquid chromatography and capillary electrophoresis. J Pharm Biomed Anal 19:435–442
• Rabinow BE (2004) Nanosuspensions in drug delivery. Nat Rev Drug Discov 3:785–796
• Raffa V, Vittorio O, Riggio C, Cuschieri A (2010) Progress in nanotechnology for healthcare. Minim Invas Ther Allied Technol 19:127–135
• Rahman N, Khan NA, Azmi SN (2004) Kinetic spectrophotometric method for the determination of silymarin in pharmaceutical formulations using potassium permanganate as oxidant. Pharmazie 59:112–116
• Santos FK, Oyafuso MH, Kiill CP, Gremião MPD, Chorilli M (2013) Nanotechnology-based drug delivery systems for treatment of hyperproliferative skin diseases—a review. Curr Nanosci 9:159–167
• Schaffazick SR, Guterres SS, Freitas LL, Pohlmann AR (2003) Characterization and physicochemical stability of nanoparticle polymeric systems for drug administration. Quim Nova 26:726–737
• Schwendener RA, Schott H (1996) Lipophilic 1-beta-D-arabinofuranosyl-cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model. J Cancer Res Clin Oncol 122:723–726
• Serajuddin ATM (1999) Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems and recent breakthroughs. J Pharm Sci 88:1058–1066
• Serajuddin ATM, Shee PC, Mufson D, Bernstein DF, Augustine MA (1988) Effect of vehicle amphiphilicity on the dissolution and bioavailability of a poorly water-soluble drug from solid dispersion. J Pharm Sci 77:414–417
• Seyfoddin A, Shaw J, Al-Kassas R (2010) Solid lipid nanoparticles for ocular drug delivery. Drug Deliv 17:467–489
• Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M (2007a) Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm 66:227–243
• Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M (2007b) Design and development of ramipril nanoemulsion formulation: in vitro and in vivo assessment. J Biomed Nanotechnol 3:28–44
• Shakeel F, Anwer MK (2015) Dissolution thermodynamics and solubility of silymarin in PEG 400-water mixtures at different temperatures. Drug Dev Ind Pharm 41:1819–1823
• Shakeel F, Shafiq S, Haq N, Alanazi FK, Alsarra IA (2012) Nanoemulsions as potential vehicles for transdermal and dermal delivery of hydrophobic compounds: an overview. Expert Opin Drug Deliv 9:953–954
• Shakeel F, Anwer MK, Shazly GA, Jamil S (2014) Measurement and correlation of solubility of bioactive compound silymarin in five different green solvents at 298.15 K to 333.15 K. J Mol Liq 195:255–258
• Shi J, Votruba AR, Farokhzad OC, Langer R (2010) Nanotechnology in drug delivery and tissueengineering: from discovery to applications. Nano Lett 10:3223–3230
• Sintov AC, Shaprio L (2004) New microemulsions vehicle facilitates percutaneous penetration in vitro and cutaneous drug bioavailability in vivo. J Control Release 95:173–183
• Slowing II, Vivero-Escoto JL, Wu CW, Lin VSY (2008) Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 60:1278–1288
• Sonali D, Tejal S, Vaishali T, Tejal G (2010) Silymarin-solid dispersions: characterization and influence of preparation methods on dissolution. Acta Pharm 60:427–443
• Souto EB, Severino P, Santana MHA, Pinho SC (2011) Solid lipid nanoparticles: classical methods of laboratory production. Quim Nova 34:1762–1769
• Stella VJ, Haslam J, Yata N, Okada H, Lindenbaum S, Higuchi T (1978) Enhancement of bioavailability of a hydrophobic amine antimalarial by formulation with oleic acid in a soft gelatin capsule. J Pharm Sci 67:1375–1377
• Sun N, Wei X, Wu B, Chen J, Lu Y, Wu W (2008a) Enhanced dissolution of silymarin/polyvinylpyrrolidone solid dispersion pellets prepared by a one-step fluid-bed coating technique. Powder Technol 182:72–80
• Sun N, Zhang X, Lu Y, Wu W (2008b) In vitro evaluation and pharmacokinetics in dogs of solid dispersion pellets containing Silybum marianum extract prepared by fluid-bed coating. Planta Med 74:126–132
• Tekade RK, Dutta T, Gajbhiye V, Jain NK (2009) Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics. J Microencapsul 26:287–296
• Toguchi H, Ogawa Y, Iga K, Yashiki T, Shimamoto T (1990) Gastrointestinal absorption of ethyl 2-chloro-3-(4-(2-methyl-2- phenylpropyloxy) phenyl) propionate from different dosage forms in rats and dogs. Chem Pharm Bull 38:2792–2796
• Trewyn BG, Slowing II, Giri S, Chen HT, Lin VSY (2007) Synthesis and functionalization of a mesoporous silica nanoparticle based on the sol-gel process and applications in controlled release. Acc Chem Res 40:846–853
• Tyler V (1994) Phytomedicines in Western Europe: their potential impact on herbal medicine in the United States. Herbalgram 30:24–30
• Wagner V, Dullaart A, Bock A, Zweck A (2006) The emerging nanomedicine landscape. Nat Biotechnol 24:1211–1217
• Wang K, Zhang H, Shen L, Du Q, Li J (2010) Rapid separation and characterization of active flavonolignans of Silybum marianum by ultra-performance liquid chromatography coupled with electrospray tandem mass spectrometry. J Pharm Biomed Anal 53:1053–1057
• Wei W, Yang W, Li Q (2006) Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. Eur J Pharm Biopharm 63:288–294
• Wissing SA, Kayserb O, Mü ller RH (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56:1257–1272
• Wu JW, Lin LC, Hung SC, Chi CW, Tsai TH (2007) Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. J Pharm Biomed Anal 45:635–641
• Wu JW, Lin LC, Tsai TH (2009) Drug-drug interactions of silymarin on the perspective of pharmacokinetics. J Ethnopharmacol 121:185–193
• Xiao YY, Song YM, Chen ZP, Ping QN (2005) Preparation of silymarin proliposomes and its pharmacokinetics in rats. Yao Xue Xue Bao 40:758–763
• Xie Y, Lu Y, Qi J, Li X, Zhang X, Han J, Jin S, Yuan H, Wu W (2013) Synchronized and controlled release of multiple components in silymarin achieved by the osmotic release strategy. Int J Pharm 441:111–120
• Xu XM, Li Q, Zhu Y, Shen S, Shen Z, Yu JN (2005) Study on the preparation and bio-distribution of silybin lipid nanospheres. Zhongguo Zhong Yao ZaZhi 30:1912–1914
• Yanyu X, Yunmei S, Zhipeng C, Qineng P (2006a) The preparation of silybin-phospholipid complex and the study of its pharmacokinetics in rats. Int J Pharm 307:77–82
• Yanyu X, Yun-mei S, Zhi-peng C, Qi-neng P (2006b) Preparation of silymarin proliposome: a new way to increase oral bioavailability of silymarin in beagle dogs. Int J Pharm 319:162–168
• Yue X, Jing Y, Dai Z (2011) Liposomal cerasome: a nanohybrid of liposome and silica. Asia Pac J Chem Eng 6:569–574
• Zhang JQ, Liu J, Li XL, Jasti BR (2007) Preparation and characterization of solid lipid nanoparticles containing silibinin. Drug Deliv 14:381–387
• Zhang P, Ye H, Min T, Zhang C (2008) Water soluble poly (ethylene glycol) prodrug of silybin: design, synthesis, and characterization. J Appl Polym Sci 107:3230–3235
• Zhao J, Agarwal R (1999) Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcin 20:2101–2108
• Zimmerman N, Swafford A, Pantano P, Chakravarty P (2008) Thermal ablation of tumor cells with antibody-functionalized single-walled carbon nanotubes. Proc Natl Acad Sci 105:8697–8702

Identyfikatory

DOI

10.1007/s11738-015-2008-3